ReviewTranslational lung cancer research2019
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.
Review in Translational lung cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Cisplatin-Resistant Lung Adenocarcinoma Cells Exhibit Increased Proangiogenic Capacity in a Microphysiological Model of Tumor Neovascularization.Cancer medicine · 2026Article
- Propyl gallate induces human pulmonary fibroblast cell death through the regulation of Bax and caspase-3.Annals of medicine · 2024Article
- Article
- Propyl gallate induces cell death in human pulmonary fibroblast through increasing reactive oxygen species levels and depleting glutathione.Scientific reports · 2024Article
- IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.Immunotherapy · 2024Article
- Non-Coding RNAs as Key Regulators in Lung Cancer.International journal of molecular sciences · 2023Review
- Construction and validation of a novel prognostic nomogram for predicting overall survival in lung adenocarcinoma patients with different patterns of metastasis.Journal of cancer research and clinical oncology · 2023Article
- Dissecting the single-cell transcriptome network of macrophage and identifies a signature to predict prognosis in lung adenocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Ebselen Inhibits the Growth of Lung Cancer Cells via Cell Cycle Arrest and Cell Death Accompanied by Glutathione Depletion.Molecules (Basel, Switzerland) · 2023Article
- Enhanced recovery of postoperative nursing for single-port thoracoscopic surgery in lung cancer patients.Frontiers in oncology · 2023Review
- Article
- Tempol Inhibits the Growth of Lung Cancer and Normal Cells through Apoptosis Accompanied by Increased OMolecules (Basel, Switzerland) · 2022Article
- The Anti-Apoptotic Effects of Caspase Inhibitors in Propyl Gallate-Treated Lung Cancer Cells Are Related to Changes in Reactive Oxygen Species and Glutathione Levels.Molecules (Basel, Switzerland) · 2022Article
- Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.Immunotherapy · 2021Review
- Tempol differently affects cellular redox changes and antioxidant enzymes in various lung-related cells.Scientific reports · 2021Article
- Role of Immune Checkpoint Inhibitor Therapy in AdvancedFrontiers in oncology · 2021Review
- Mouse lung automated segmentation tool for quantifying lung tumors after micro-computed tomography.PloS one · 2021Article
- Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Article
- Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2.Translational lung cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There were many clinical studies on lung cancer in 2018. In particular, significant progress has been made in immunotherapy and targeted therapy. Whether in small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have shown good results. For patients with specific gene mutations, the new generation inhibitors also showed good results in clinical trials. In this review, we summarize the clinical trials in lung cancer in 2018 and describe the progress and prospects for lung cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.